133 related articles for article (PubMed ID: 38636314)
1. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Liu S; Graves N; Tan AC
Lung Cancer; 2024 May; 191():107794. PubMed ID: 38636314
[TBL] [Abstract][Full Text] [Related]
2. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
Arriola E; Bernabé R; Campelo RG; Biscuola M; Enguita AB; López-Ríos F; Martínez R; Mezquita L; Palanca S; Pareja MJ; Zugazagoitia J; Arrabal N; García JF; Carcedo D; de Álava E
JCO Precis Oncol; 2023 Mar; 7():e2200546. PubMed ID: 36862967
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
Englmeier F; Bleckmann A; Brückl W; Griesinger F; Fleitz A; Nagels K
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1495-1511. PubMed ID: 35532791
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.
de Alava E; Pareja MJ; Carcedo D; Arrabal N; García JF; Bernabé-Caro R
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):1033-1042. PubMed ID: 35593180
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
[TBL] [Abstract][Full Text] [Related]
19. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
20. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
